Current Report Filing (8-k)
November 22 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2019
Zymeworks Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
British Columbia, Canada
|
|
001-38068
|
|
47-2569713
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
|
V6H 3V9
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(604) 678-1388
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Shares, no par value per share
|
|
ZYME
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On November 22, 2019, Zymeworks Inc. (Zymeworks) issued a press release announcing updated Phase 1 data for single agent ZW25 in heavily
pretreated patients with HER2-expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, at the ESMO Asia 2019 Congress, taking
place November 2224 in Singapore.
On November 22, 2019, this press release was filed with the Canadian securities regulatory authorities in
Canada on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com. Additionally, on November 22, 2019, Zymeworks filed a material change report regarding this matter with the Canadian securities regulatory
authorities on SEDAR at www.sedar.com. Copies of this press release and material change report are respectively filed as exhibits 99.1 and 99.2 hereto.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZYMEWORKS INC.
|
|
|
|
|
(Registrant)
|
Date: November 22, 2019
|
|
|
|
By:
|
|
/s/ Neil A. Klompas
|
|
|
|
|
Name:
Title:
|
|
Neil A. Klompas
Executive Vice President,
Business Operations and Chief Financial Officer
|
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2023 to Sep 2024